Stay updated on Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the ongoing phase I trial studying the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with metastatic genitourinary tumors.
    Difference
    0.0%
    Check dated 2024-06-06T14:31:51.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for patients, specifying the required health conditions and prior treatments for participation. Previously, this section indicated that no information was provided.
    Difference
    58%
    Check dated 2024-05-22T20:29:03.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T22:35:31.000Z thumbnail image

Stay in the know with updates to Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Immunotherapy in Genitourinary Tumors Clinical Trial page.